Navigation Links
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Date:11/11/2008

ntestinal permeability-inflammation loop. Larazotide acetate inhibits tight junction opening triggered by both gluten and inflammatory cytokines, thus reducing uptake of gluten. Larazotide acetate disrupts the intestinal permeability-inflammation loop, and reduces symptoms associated with celiac disease. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn's Disease. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is located in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Media: Mariesa Kemble

Sam Brown Communications

608-850-4745

kemblem@aol.com

Corporate: Wendy Perrow, MBA

Alba Therapeutics Corporation

410-878-9850

info@albatherapeutics.com

http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
6. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
7. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
8. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
9. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Pharmaceutical Research and Manufacturers of ... last year in the research and development (R&D) of ... majority of all biopharmaceutical R&D spending – both public ... . The new R&D numbers, the result of ... in the newly released PhRMA 2015 Biopharmaceutical ...
(Date:4/20/2015)... April 20, 2015 Stand Up To Cancer (SU2C) and ... $20 million Dream Team to attack the number one cancer ... Meeting of the American Association for Cancer Research (AACR), Scientific ... people in the United States will ... 158,040 will die from it, making lung cancer the leading ...
(Date:4/20/2015)... PALO ALTO, Calif. , April 20, 2015 ... study demonstrate positive trends in the ability of ... slow the progression of amyotrophic lateral sclerosis (ALS, ... over a 6-month treatment period. While NP001,s slowing ... of the study was not statistically significant, clinically ...
Breaking Medicine Technology:PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... N.Y., March 2, 2011 Lixte ... that the company has received a $244,479.25 grant ... awarded to further development and commercialization of Lixte,s novel anti-cancer ... the Patient Protection and Affordable Care Act of 2010 to ...
... 2011 InspireMD , developer ... has expanded its MGuard production facilities to meet the ... accelerating demand for MGuard include the recent recommendation of ... be considered for PCI of highly thrombotic or SVG ...
Cached Medicine Technology:Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government 2InspireMD Boosts MGuard Production Capacity 2
(Date:4/20/2015)... California (PRWEB) April 20, 2015 At ... Entertainment held the “RockNRolla Movie Awards” EcoLuxe Lounge, with ... Los Angeles’ leading producer of sustainable product placement in ... providers of socially conscious and ecologically sound goods and ... film star Chase Masterson hosted the Choices Celebrity Interview ...
(Date:4/20/2015)... 2015 Goodreads is sponsoring a book ... It’s Good for You and Your Company between Mar. ... and Rick Lindquist have released a new book ... Good for You and Your Company. The book discusses ... woes - employer-funded individual health insurance. , According ...
(Date:4/20/2015)... Early registration is open for the ... space at the start line. Returning to James Kealoha ... limited to 500 participants (actually there’s only 499 spots since ... , Now thru April 30, the entry fee is only ... May 1st, the fee goes up to $200 and $100, ...
(Date:4/20/2015)... TROY Healthcare Solutions will be hosting an ... which provides the ultimate level of security for prescriptions, ... Anthem Suite Hotel in the Socrates Room, located at ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief 15-20 minute presentations each hour ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 "It's so ... done for our family. Initially, I really thought I ... it would end. But what I've discovered is this ... to be together, support each other and walk through ... Keller. "I have learned way more from these families ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 2Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 3
... What: Sacramento - On Tuesday, April 28, at 1:30 p.m., Donate, ... press conference to announce, Padilla,s ... grade health classes to include 15 minutes of education regarding, ... bill ultimately, would provide California ...
... total $36.1 million, an increase of 22% over 2007- ... for the fourth quarter, $14.4 million for the full ... (Nasdaq: ENCO ), a full service ... and management capabilities for clinical trials and patient registries ...
... Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, ... on its corporate activities. , One of the ... previous financial disclosures, is the conclusion of a ... Complex (MCC), formulated as Urocidin(TM), for the intravesical ...
... Smoke-Free Restaurants, Bars and Workplaces StatewideAUSTIN, Texas, April ... committee prepares to consider comprehensive smoke-free workplace legislation ... is launching a radio advertising campaign urging the ... all Texans from harmful secondhand smoke.(Logo: ...
... Colo., April 27 Heska Corporation (Nasdaq: HSKA ... Heska Corporation Invites You to Listen to Its ... May 5, @ 9:00 a.m. (MDT)Where: www.heska.com ... on the front page of this website)How: ...
... a complimentary resource that can assist in planning for, controlling and ... ... TX (PRWEB) April 27, 2009 -- With more than 100 deaths ... swine influenza outbreak has triggered global concern as governments everywhere scramble ...
Cached Medicine News:Health News:Donate Life California to Hold Press Conference on Organ Donation Education, April 28, 1:30 p.m., on State Capitol West Steps 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Bioniche Provides a Corporate Update 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 3
... The SmartPulse 10.6 CO2 system was expressly ... in cosmetic surgery. A special source and ... it possible to create particular high energy ... impulses (technically known as 'top-flat shaped') allow ...
... laser is the ideal instrument for safe, ... Plus, the majority of surface lesions can ... range of scar tissue, with a minimum ... with the elimination of anaesthetics, risks and ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... and efficient method applied to dermatological therapy ... research and development with hundreds of users, ... source, but rather a platform for future ... in pulsed-light-based technology, the most valid and ...
Medicine Products: